Application of Targeted Axillary Lymph Node Resection in Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: an Open-label, Multicenter Study

NCT07032220 | Active Not Recruiting

• 1 other identifier: FujianUnions
• Study Type: interventional
• Target: 175
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, following the full informed consent of patients regarding the safety and potential benefits of the new intervention regimen, pathologically confirmed lymph nodes were pre-labeled with carbon nanoparticles prior to neoadjuvant chemotherapy. This was done to investigate the detection rate of carbon nanoparticle-labeled lymph nodes and to assess the stability and safety of carbon nanoparticles. Additionally, the dye single tracer method was employed for sentinel lymph node biopsy to evaluate the false-negative rate of TAD. This is an open-label, single-arm, multi-center prospective clinical trial. The primary objectives of this study are to evaluate the accuracy, feasibility, and safety of this method, thereby improving the quality of life and reducing postoperative complications for breast cancer patients while ensuring treatment efficacy.

Conditions

Breast Cancer Surgery; Neoadjuvant Therapy; Sentinel Lymph Node Biopsy (SLNB)

Outcome Measures

Primary Outcomes (1)

• By analyzing the detection rate of TAD, FNR and NPV, the feasibility and accuracy of this method in evaluating axillary lymph nodes of breast cancer patients after neoadjuvant therapy were evaluated.

  24 months

Secondary Outcomes (1)

• The feasibility and accuracy of TLNB and SLNB in axillary lymph node evaluation were evaluated by analyzing the detection rate of TLNB and SLNB, FNR and NPV.

  24 months

Other Outcomes (1)

• Evaluate the safety of carbon nanoparticles in breast cancer lymph node labeling

  24 months

Study Arms (1)

Feasibility and Accuracy of Targeted Axillary Dissection of Carbon Tattooing

EXPERIMENTAL

Drug: carbon suspension

Interventions

carbon suspension DRUG

Before primary systemic therapy, a core needle biopsy or fine-needle aspiration of the most suspicious axillary lymph node was performed.22 Sterile black carbon suspension (0.5 mL: 25 mg, Chongqing LUMMY Pharmaceutical Co) was injected in the cortex of the metastatic node under ultrasound guidance using a 25G needle by a trained ultrasonographer at the time of biopsy or during a separate session. The injection volume was recorded and varied depending on node size and operator. The trained ultrasonographer had more than 5 years of puncture experience. Of note, for the patients with multiple abnormal nodes or N3 disease under ultrasound at diagnosis, only the pathologically-proven lymph node is marked with carbon suspension.

Feasibility and Accuracy of Targeted Axillary Dissection of Carbon Tattooing

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• women aged 18-70 years
• The primary breast lesion was confirmed as invasive breast cancer by core needle biopsy
• Axillary lymph node metastasis confirmed by fine needle aspiration or core needle biopsy
• plan to undergo neoadjuvant chemotherapy
• operable breast cancer
• Patients with good heart, lung, liver, and kidney function are suitable for surgery
• Informed consent

You may not qualify if:

• Surgery is not planned or impossible
• Metastasis of supraclavicular lymph nodes
• distant metastasis, excluding bone metastasis
• previous ipsilateral axillary surgery or radiotherapy
• Due to personal or family factors, the patient is unable to cooperate with the surgical treatment recommended by the doctor according to the condition (breast conserving surgery or radical surgery).
• Patients with severe heart and lung diseases, uncontrolled infectious diseases and other non-tumor related diseases could not tolerate comprehensive treatment such as surgery and chemotherapy
• Unable to sign the informed consent form due to mental illness or other reasons
• Poor medical compliance, and the study group believed that the patients could not complete the trial treatment process and follow-up according to the standard

Sponsors & Collaborators

• Fujian Medical University Union Hospital: lead

Study Sites (1)

Study Officials

Fuzhou, Fujian, 350001, China

Location

Study Officials

• Chuan Wang

  Fujian Medical University Union Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: archiater

Study Record Dates

• First Submitted: June 4, 2025
• First Posted: June 22, 2025
• Study Start: December 9, 2024
• Primary Completion (Estimated): January 31, 2027
• Study Completion (Estimated): January 31, 2028
• Last Updated: June 22, 2025

Record last verified: 2025-06

Locations

CN (1)